iBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2.

Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.  

Seattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.

Norwood, Massachusetts-based Corbus Pharmaceuticals’ shares plunged 77% at news the company’s lenabasum failed to hit the primary endpoint in the Phase III RESOLVE-1 trial of diffuse cutaneous systemic sclerosis (SSc).

Framingham, Massachusetts-based Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging (NIA), part of the National Institutes of Health, to assist with a Phase III clinical trial of ALZ-801.

According to a study published in Nature Communications, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.

Researchers at the University of California, San Francisco (UCSF) synthesized a molecule inspired by llama antibodies called nanobodies that could neutralize SARS-CoV-2, the virus that causes Covid-19.

The medical cannabis market in the United States, even with all of its restrictions, continues to be a fertile area not only for dispensaries, but pharma companies developing cannabis-derived drugs; and proponents say further growth can be generated by educating physicians about medical cannabis.

Biogen inked a binding deal to co-develop and co-commercialize Denali Therapeutics’ small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.

ARC Therapeutics launched with a $6 million financing led by founding investor Eshelman Ventures LLC.